ReVance Therapeutics Receives $45,000,000 Series E Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=91f64ff4-4c59-42a6-92f1-2ee436eedab0&Preview=1 - Date
6/10/2011 - Company Name
ReVance Therapeutics - Mailing Address
7555 Gateway Boulevard Newark, CA 94560 - Company Description
Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin. The technology is being designed and tested to eliminate the need for needle injections, while permitting a safe, local, targeted, and painless approach to treat facial aesthetics and hyperhidrosis. - Website
http://www.revance.com - Transaction Type
Venture Equity - Transaction Amount
$45,000,000 - Transaction Round
Series E - Proceeds Purposes
The will continue to develop its topical and injectable neuromodulation pipeline in both aesthetic and therapeutic categories. - M&A Terms
- Venture Investor
Essex Woodlands Health Ventures - Venture Investor
Essex Woodlands Health Ventures - Venture Investor
Vivo Ventures - Venture Investor
Technology Partners - Venture Investor
NovaQuest - Venture Investor
Shepherd Ventures - Venture Investor
Palo Alto Investors - Venture Investor
Pac-Link Bio
